Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Gilead Sciences (GILD) closed at $113.03 in the latest trading session, marking a -2.73% move from the prior day. This change lagged the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw a downswing of 0.14%, while the tech-heavy Nasdaq appreciated by 0.33%. Coming into today, shares of the HIV and hepatitis C drugmaker had gained 5% in the past month. In that same time, the Medical sector gained 1.92%, while the S&P 500 gained 4.93%. The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings report is expected on August 7, 2025. The company's earnings per share (EPS) are projected to be $1.96, reflecting a 2.49% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.95 billion, down 0.1% from the year-ago period. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $8.02 per share and revenue of $28.67 billion. These totals would mark changes of +73.59% and -0.28%, respectively, from last year. Investors should also note any recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.37% higher. Right now, Gilead Sciences possesses a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Gilead Sciences has a Forward P/E ratio of 14.48 right now. This represents a discount compared to its industry average Forward P/E of 20.33. One should further note that GILD currently holds a PEG ratio of 0.73. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.75 as trading concluded yesterday. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Should You Invest in Gilead Sciences, Inc. (GILD)?Before you invest in Gilead Sciences, Inc. (GILD), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks